Harnessing Immunostimulatory Gene Therapy through Oncolytic Viruses
The strategy of Lokon is to modulate the tumor microenvironment and simultaneously activate the immune system to attack the tumor using immunostimulatory gene therapy (armed oncolytic adenoviruses).
We are announcing a new position (employment or consultant) at Lokon as a QA/QC within GLP and GMP situated in Sweden. See the announcement at "Job Opportunities".
Lokon announces a collaboration to combine LOAd703 with checkpoint blockade antibody treatments in pancreatic cancer and melanoma. See the press release.
Congratulations to Jessica Wenthe at Uppsala University who presented Lokons virus projects at ESMO in Munich and was awarded the Best Poster in the immunotherapy session.
The first patient has been enrolled in our Swedish trial (pancreatic-, biliary-, colorectal-, and ovarian cancer).
Our clinical trial for patients with pancreatic cancer in Houston has now treated the first patient!
EMA has granted Lokon an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.
FDA has granted Lokon an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.
Copyright ©2014, All other marks are the property of their respective owners.